Xilio Therapeutics Inc
Change company Symbol lookup
Select an option...
XLO Xilio Therapeutics Inc
HUN Huntsman Corp
IART Integra Lifesciences Holdings Corp
R Ryder System Inc
AAPL Apple Inc
IIM Invesco Value Municipal Income Trust
QQQ Invesco QQQ Trust
VZ Verizon Communications Inc
CHTR Charter Communications Inc
SPB Spectrum Brands Holdings Inc
Go

Company profile

Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by tumor microenvironment (TME)-associated proteases.

Price
Delayed
$2.48
Day's Change
0.02 (0.81%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.55
Day's Low
2.45
Volume
(Light)

Today's volume of 25,735 shares is on pace to be much lighter than XLO's 10-day average volume of 131,703 shares.

25,735

Company Profile

Xilio Therapeutics, Inc. is a biotechnology company. The Company is focused on harnessing the immune system to achieve clinical responses for cancer patients. It offers a geographically precise solutions (GPS) platform to engineer molecules, including cytokines and other biologics, that are designed to enhance therapeutic index. Using its GPS platform, the Company is engaged in developing a pipeline of tumor-selective cytokine and checkpoint inhibitor immunotherapies to treat cancer. Its product candidates include XTX101, XTX202, XTX301, and XTX401. XTX101 is a clinical-stage, tumor-selective anti-cytotoxic T-lymphocyte-associated protein (CTLA-4), monoclonal antibody (mAb), which is designed to improve upon the therapeutic index of existing anti-CTLA-4 therapies. XTX202 and XTX301 are an engineered form of interleukin 2 (IL-2) that is masked with a protein domain to prevent binding activity until the protein domain is cleaved off by tumor microenvironment (TME)-associated proteases.

Valuation Ratios

No valuation ratios available.

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

July 2022
Current Month
27.8K
Previous Month
53.6K
Percent of Float
0.11%
Days to Cover
0.6041 Days

Share Information

XLO is in a share class of common stock
Float
25.4M
Shares Outstanding
27.5M
Institutions Holding Shares
54
74.37%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Paul J. ClancyChmn.
  • Martin H. HuberPres.
  • Rene RussoCEO
  • Salvatore GiovineCFO
  • Joseph L. FarmerCOO

Address

  • 828 Winter Street, Suite 300
  • Waltham, MA 02451
  • Phone: (617) 430-4680
  • Fax: (302) 655-5049
  • https://xiliotx.com/

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.